https://scholars.lib.ntu.edu.tw/handle/123456789/480219
標題: | Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: A systematic review | 作者: | Falagas M.E. Valkimadi P.-E. YU-TSUNG HUANG Matthaiou D.K. PO-REN HSUEH |
公開日期: | 2008 | 卷: | 62 | 期: | 5 | 起(迄)頁: | 889-894 | 來源出版物: | Journal of Antimicrobial Chemotherapy | 摘要: | Background: Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen, causing infections whose management is often problematic due to its inherent resistance to many antibiotics, making co-trimoxazole the main therapeutic option. However, there are cases in which either due to antimicrobial resistance or allergic reactions and intolerance to co-trimoxazole this antibiotic cannot be administered. We sought to evaluate the available clinical evidence regarding potentially effective alternative antibiotics for the treatment of S. maltophilia infections. Methods: The literature search was performed in the PubMed and Scopus databases. The search string used was 'Stenotrophomonas maltophilia OR Xanthomonas maltophilia'. Results: Thirty-one case reports and 5 case series were retrieved including a total of 49 patients with a variety of infections. Twenty of 49 cases (40.8%) were treated with ciprofloxacin as monotherapy or in combination with other antibiotics; 12 of 49 cases (24.5%) were treated with ceftriaxone- or ceftazidime-based regimens; and 6 of 49 cases (12.2%) were treated with ticarcillin- or ticarcillin/clavulanate-based regimens. The cure or improvement rates were 18 cases (90%), 8 (75%) and 4 (66.7%), respectively. The remaining 11 patients received various antimicrobials including aminoglycoside-based regimens, carbapenems, levofloxacin, chloramphenicol, aztreonam, minocycline and other β-lactams. Conclusions: The limited available data suggest that ciprofloxacin, ceftazidime or ceftriaxone, and ticarcillin/clavulanate, alone or in combination with other antibiotics, may be considered as alternative options beyond co-trimoxazole. ? The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/480219 | ISSN: | 0305-7453 | DOI: | 10.1093/jac/dkn301 | SDG/關鍵字: | amikacin; aminoglycoside antibiotic agent; amoxicillin plus clavulanic acid; ampicillin; antibiotic agent; aztreonam; beta lactam antibiotic; carbapenem derivative; cefoperazone; cefozopran; ceftazidime; ceftriaxone; chloramphenicol; ciprofloxacin; cotrimoxazole; gentamicin; imipenem; isepamicin; levofloxacin; meropenem; minocycline; netilmicin; piperacillin; piperacillin plus tazobactam; sulfadimidine; teicoplanin; ticarcillin; timentin; tobramycin; unindexed drug; clinical trial; combination chemotherapy; drug choice; drug efficacy; evidence based medicine; Gram negative infection; human; medical literature; MEDLINE; monotherapy; review; Stenotrophomonas maltophilia; systematic review; Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Stenotrophomonas maltophilia; Trimethoprim-Sulfamethoxazole Combination |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。